Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Riess

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Clinical Lung Cancer|August 30, 2025
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung CancerFangdi Sun, Seema Nagpal, Surbhi Singhal, et al.
JTO Clinical and Research Reports|December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLCMatthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2023
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung CancerMiguel Lopez de Rodas, Yvonne Wang, Gang Peng, et al.
Cancer Investigation|February 25, 2012
Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancerJonathan W Riess, Aaron C Logan, Yelena Krupitskaya, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2025
Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CTClemens Mingels, Mohammad H Madani, Fatma Sen, et al.
Immunopharmacology and Immunotoxicology|February 6, 2014
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patientsJonathan W Riess, Nupur Bhattacharya, Kim R M Blenman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2017
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective DatabaseSukhmani K Padda, Xiaopan Yao, Alberto Antonicelli, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2012
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapyMillie Das, Jonathan W Riess, Paul Frankel, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Clinical Lung Cancer|August 30, 2025
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung CancerFangdi Sun, Seema Nagpal, Surbhi Singhal, et al.
JTO Clinical and Research Reports|December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLCMatthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2023
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung CancerMiguel Lopez de Rodas, Yvonne Wang, Gang Peng, et al.
Cancer Investigation|February 25, 2012
Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancerJonathan W Riess, Aaron C Logan, Yelena Krupitskaya, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2025
Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CTClemens Mingels, Mohammad H Madani, Fatma Sen, et al.
Immunopharmacology and Immunotoxicology|February 6, 2014
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patientsJonathan W Riess, Nupur Bhattacharya, Kim R M Blenman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2017
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective DatabaseSukhmani K Padda, Xiaopan Yao, Alberto Antonicelli, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2012
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapyMillie Das, Jonathan W Riess, Paul Frankel, et al.
Pageof 14